METHODS: Thyroid function tests were obtained cross-sectionally from cSLE patients. Demographic, clinical, and laboratory characteristics and activity scores were collected from medical records. Patients diagnosed with cSLE were compared to the healthy control group for the frequency of thyroid dysfunction. The Mann-Whitney U, independent samples t test, and the Chi-square or Fisher\'s exact test were used to compare study groups. A p-value below 0.05 was considered statistically significant.
RESULTS: Out of 73 cSLE patients, 14 (19.1%) had subclinical hypothyroidism, 9 (12.3%) had clinical hypothyroidism, 12 (16.4%) were diagnosed with HT, and 12 (16.4%) had a family history of HT. Thyroid USG was performed in 5 euthyroid patients and 1 borderline subclinical hypothyroid patient with positive thyroid autoantibody and reported as diffuse heterogeneous echogenicity enlargement in the thyroid gland. There were no significant differences in clinical and laboratory data or medication used between the groups with and without HT; however, patients with HT had a higher frequency of clinical hypothyroidism and family history of HT. Cumulative prednisolone dose was significantly lower in patients diagnosed with HT. The frequency of HT was considerably higher in patients with cSLE compared to the healthy control group.
CONCLUSIONS: The results demonstrate an increased incidence of HT in cSLE patients, even if they are euthyroid, and recommend that cSLE patients be screened more frequently.
方法:对cSLE患者进行了甲状腺功能检查。人口统计,临床,并从病历中收集实验室特征和活动评分。将诊断为cSLE的患者与健康对照组的甲状腺功能异常频率进行比较。Mann-WhitneyU,独立样本t检验,和卡方或Fisher精确检验用于比较研究组。低于0.05的p值被认为是统计学上显著的。
结果:在73例cSLE患者中,14(19.1%)患有亚临床甲状腺功能减退症,9(12.3%)有临床甲状腺功能减退症,12例(16.4%)被诊断为HT,12例(16.4%)有HT家族史。在5例甲状腺功能正常的患者和1例甲状腺自身抗体阳性的临界亚临床甲状腺功能减退患者中进行了甲状腺USG,并报告为甲状腺弥漫性异质性回声性增大。有和没有HT的组之间的临床和实验室数据或使用的药物没有显着差异;然而,HT患者的临床甲状腺功能减退症和HT家族史发生率较高。诊断为HT的患者的累积泼尼松龙剂量显着降低。与健康对照组相比,cSLE患者的HT频率明显更高。
结论:结果表明,cSLE患者中HT的发生率增加,即使他们甲状腺功能正常,并建议对cSLE患者进行更频繁的筛查。